CLINICAL TRIALS PROFILE FOR METHYL AMINOLEVULINATE HYDROCHLORIDE
✉ Email this page to a colleague
All Clinical Trials for Methyl Aminolevulinate Hydrochloride
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00369018 ↗ | A Dose-finding Study of MAL and HAL Photodynamic Therapy of Cervical Premalignant Lesions. | Completed | Photocure | Phase 1/Phase 2 | 2006-08-01 | The study will determine the best drug (MAL or HAL) dosage for photodynamic therapy of cervical precancerous lesions (dysplasia) in women that are referred for conisation (surgery). |
| NCT00535080 ↗ | Compassionate Use of Metvix® (Methyl Aminolevulinate) Photodynamic Therapy (PDT) in Subjects With Field Actinic Keratoses, Large/Multiple Superficial Basal Cell Carcinomas (BCCs), or Bowen's Disease | No longer available | Galderma | 1969-12-31 | The aim of this study is to provide this investigational drug to patients who cannot be optimally treated with conventional therapies and to collect efficacy and safety data on the use of Metvix PDT in subjects with field actinic keratoses, large/multiple superficial basal cell carcinomas (BCCs) or Bowen's disease. | |
| NCT00535080 ↗ | Compassionate Use of Metvix® (Methyl Aminolevulinate) Photodynamic Therapy (PDT) in Subjects With Field Actinic Keratoses, Large/Multiple Superficial Basal Cell Carcinomas (BCCs), or Bowen's Disease | No longer available | Galderma R&D | 1969-12-31 | The aim of this study is to provide this investigational drug to patients who cannot be optimally treated with conventional therapies and to collect efficacy and safety data on the use of Metvix PDT in subjects with field actinic keratoses, large/multiple superficial basal cell carcinomas (BCCs) or Bowen's disease. | |
| NCT00594425 ↗ | Photodynamic Therapy (PDT) With Methyl Aminolevulinate (MAL) Cream in Moderate to Severe Acne | Completed | Photocure | Phase 2 | 2007-02-01 | This multicenter study will be divided into 2 phases. The first phase will be an open label, dose-escalation phase, while the second will be a blinded, randomized, vehicle-controlled, parallel-group, dose-response phase. The second phase will only start if the first phase succeeds in establishing well tolerated dose(s). Patients with moderate to severe acne vulgaris in the face will be included.The results from part 2 has been presented in the result section. |
| NCT00629317 ↗ | Trial of Methyl Aminolevulinate Plus Aktilite in Facial Photodamage | Completed | Galderma | Phase 3 | 2008-02-01 | The aim of the study is to determine the efficacy of MAL + Aktilite versus placebo + Aktilite in facial photodamage in a randomized double blind trial. |
| NCT00629317 ↗ | Trial of Methyl Aminolevulinate Plus Aktilite in Facial Photodamage | Completed | Galderma R&D | Phase 3 | 2008-02-01 | The aim of the study is to determine the efficacy of MAL + Aktilite versus placebo + Aktilite in facial photodamage in a randomized double blind trial. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for Methyl Aminolevulinate Hydrochloride
Condition Name
Clinical Trial Locations for Methyl Aminolevulinate Hydrochloride
Trials by Country
Clinical Trial Progress for Methyl Aminolevulinate Hydrochloride
Clinical Trial Phase
Clinical Trial Sponsors for Methyl Aminolevulinate Hydrochloride
Sponsor Name
